Literature DB >> 18840196

Primary non-Hodgkin's lymphoma of the uterus, cervix and parametrium treated by combined immunochemotherapy.

Chi-Feng Su1, Horng-Jyh Tsai, Chih Kuo, Gin-Den Chen, Long-Yau Lin, Che-Cheng Huang, Kan-Hung Luo.   

Abstract

Primary malignant lymphoma of the female genital tract is extremely rare and no standard treatment has been established. The present patient is menopausal with diffuse large B-cell lymphoma of the uterine body, endocervix and parametrium. She underwent a simple total abdominal hysterectomy and bilateral salpingo-oophorectomy, followed by treatment with a new regimen, combined immunochemotherapy with rituximab (monoclonal antibody), cyclophosphamide vincristine, and prednisolone. The patient had complete remission in the follow-up 3 years after this therapy. We suggest this treatment is a useful therapy for a patient with primary malignant lymphoma of the uterine body.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840196     DOI: 10.1111/j.1447-0756.2008.00919.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  4 in total

1.  Primary Endometrial Diffuse Large B-cell Lymphoma: A Rare Disease and Diagnostic Challenge in an Asymptomatic Postmenopausal Woman.

Authors:  Iqra Arshad; Muhammad Kafeel
Journal:  Cureus       Date:  2022-04-29

2.  Primary cervical and uterine corpus lymphoma; a case report and literature review.

Authors:  Antonios Anagnostopoulos; Niki Mouzakiti; Stuart Ruthven; Jonathan Herod; Michail Kotsyfakis
Journal:  Int J Clin Exp Med       Date:  2013-04-12

3.  Diffuse Large B-Cell Lymphoma Involvement in Two Different Localizations: A Case Report.

Authors:  Nilufer Bulut; Hılal Serap Arslan; Ipek Yıldız Ozaydın
Journal:  Surg J (N Y)       Date:  2019-03-04

Review 4.  Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.

Authors:  Jennifer L Edwards; Michael P Jennings; Michael A Apicella; Kate L Seib
Journal:  Crit Rev Microbiol       Date:  2016-01-23       Impact factor: 7.624

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.